Year 2020, Volume 4 , Issue 10, Pages 875 - 878 2020-10-01

İnflamatuvar barsak hastalığında yeni biyolojik göstergeç: Pentraxin 3
A new biological marker in inflammatory bowel disease: Pentraxin 3

Semih KALYON [1] , Yasemin GÖKDEN [2] , Fırat OYMAN [3]


Amaç: Pentraxin 3, inflamasyonu gösterdiği bilinen, ancak İBH hastalarında güncel literatürde birbirleri ile çelişkili ve az sayıda çalışma yapılan moleküldür. Bizde bu çalışmamız da PTX3’ün İBH hastalarında Crohn ve Ülseratif kolit hastalarının ayırımında kullanılıp kullanılamayacağını, PTX3 ile hastalığın aktivitesi, tutulan barsak segmenti ve uzunluğu ile korelasyonu olup olmadığını araştırmayı amaçladık. Yöntemler: Etik kurul onayı bu prospektif vaka kontrol çalışması için alındı. 18 yaşından büyük, gebeliği, malignitesi, akut/kronik enfeksiyöz veya inflamatuvar hastalığı olmayan İBH tanılı hastalar alındı. Kontrol grubu olarak ta sağlıklı gönüllüler çalışmaya dahil edildi. Kanda PTX3 seviyesi bakıldı. Sonuçlar NCSS 2007 programı ile istatistiksel olarak analiz edildi. Bulgular: 56 kadın, 42 erkek katılımcının ortalama yaşı 37 idi (25 CH, 43 ÜK, 30 kontrol). Ülseratif kolit grubunda Trulove Witts skoru, Mayo skoru ile ilişkiye sahip olmayan PTX3, pankolit tutulumlu hastalarda istatistiksel olarak anlamlı daha yüksekti (P<0.05, P=0.046 sırasıyla). Crohn hastalığı grubunda tutulum yeri, davranış paterni, CDAI skoru ve aktivite ile PTX3 arasında istatistiksel bir ilişki saptanmadı (P<0.05). Sonuç: PTX3 İBH aktivasyonunun takibinde uygun bir biomarker değildir ve iki alt tipi birbirinden ayıramaz. Crohn hastalarında gerek davranış paterni gerekse tutulum yerini belirtmede yetersizdir. Ancak Ülseratif kolit hastalarının takibinde endoskopik inceleme olmadan tutulan kolon alanının yaygınlığını gösterebilir, dolayısıyla Ülseratif kolit hastalarının kontrol endoskopi zamanları gelene kadar ki ara dönemde PTX3 düzeyleri takip edilerek tutulan barsak alanının tüm kolonu etkileyip etkilemediği izlenebilir.
Aim: Pentraxin 3 is a molecule that is known to show inflammation, however few studies with contradictory results have been conducted in current literature in Inflammatory Bowel Disease patients regarding PTX3. We aimed to investigate whether PTX3 can be used in the discrimination of Crohn’s disese and Ulcerative colitis patients and whether there is a correlation of PTX3 with disease activity, involved intestinal segments and their length. Method: Ethical committee approval was obtained for this a prospective, single-centered, single-blind study. IBD patients who were older than 18 years old, without pregnancy, malignancy, acute/chronic infections or inflammatory diseases were included. Healthy volunteers were included in study as a control group. PTX3 levels were measured in the blood. Shapiro-Wilk, Mann-Whitney U, Kruskal Wallis, Bonferroni-Dunn, Spearman tests were used with NCSS 2007 program. Results: The median age of the 56 male and 42 female participants was 37 years (25 CD, 43 UK and 30 controls). In the UK group, PTX3, which did not have relationship with the Trulove Witts score or the Mayo score; was a statistically significant higher in patients with pancolitis. There was no relationship between PTX3 levels and involvement, behavior pattern, CDAI scores and activity of the disease in CD group. Conclusion:PTX3 is not an appropriate biomarker for monitoring the activation of İBD and it can’t distinguish two subtypes from eachother. PTX3 is insufficient to indicate both the behavior pattern and the location of involvement in CD patients. Only, until the control endoscopy times of the patients with UK, it can be monitored whether the disease affects the entire colon by following the PTX3 levels in the interim period.
  • 1. Chen J, Xu X, Xia L, Xi X, Liu B, Yang M. Serum pentraxin 3 is a novel marker in Crohn’s disease. Mol Med Rep. 2015 Jul;12(1):543-6. doi:10.3892/mmr.2015.3451. Epub 2015 Mar 6.
  • 2. Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol. 2017 Feb;52(2):125-135. doi: 10.1080/00365521.2016.1235224. Epub 2016 Sep 27.
  • 3. Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther. 2016;7(1):5-20.
  • 4. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942-51.
  • 5. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, at al. Modified atherogenic lipoproteins induce expression of pentraxin 3 by human vascular smooth muscle cells. Atherosclerosis 175: 221 228, 2004.
  • 6. Fazzini F, Peri G, Doni A, Dell'Antonio G, Cin ED, Bozzolo E, et al. PTX3 in small vessel vascu¬litides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 44: 2841 2850, 2001.
  • 7. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Gonzalez SP, et al. Selective up regu¬lation of the soluble pattern recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 64: 854 865, 2012.
  • 8. Kato S, Ochiai M, Sakurada T, Ohno S, Miyamoto K, Sagara M, et al. Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. Dig Dis Sci. 2008;53(7):1910-6.
  • 9. Savchenko AS, Inoue A, Ohashi R, Jiang S, Hasegawa G, Tanaka T, et al. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011 May;61(5):290-7. doi: 10.1111/j.1440-1827.2011.02651.x. Epub 2011 Mar 17.
  • 10. Kato S, Ochiai M, Sakurada T, Ohno S, Miyamoto K, Sagara M, et al. Increased Expression of Long Pentraxin PTX3 in Inflammatory Bowel Diseases. Dig Dis Sci. 2008 Jul;53(7):1910-6. Epub 2007 Nov 8.
Primary Language en
Subjects Medicine
Journal Section Research article
Authors

Orcid: 0000-0003-4207-0800
Author: Semih KALYON (Primary Author)
Institution: Prof. Dr. Cemil Taşcıoğlu City Hospital
Country: Turkey


Orcid: 0000-0001-6767-3072
Author: Yasemin GÖKDEN
Institution: Prof. Dr. Cemil Taşcıoğlu City Hospital
Country: Turkey


Orcid: 0000-0001-9936-3562
Author: Fırat OYMAN
Institution: Prof.Dr. Cemil Taşcıoğlu City Hospital
Country: Turkey


Dates

Publication Date : October 1, 2020

Bibtex @research article { josam791156, journal = {Journal of Surgery and Medicine}, issn = {}, eissn = {2602-2079}, address = {jsurgmed@gmail.com}, publisher = {Fatih BAŞAK}, year = {2020}, volume = {4}, pages = {875 - 878}, doi = {10.28982/josam.791156}, title = {A new biological marker in inflammatory bowel disease: Pentraxin 3}, key = {cite}, author = {Kalyon, Semih and Gökden, Yasemin and Oyman, Fırat} }
APA Kalyon, S , Gökden, Y , Oyman, F . (2020). A new biological marker in inflammatory bowel disease: Pentraxin 3 . Journal of Surgery and Medicine , 4 (10) , 875-878 . DOI: 10.28982/josam.791156
MLA Kalyon, S , Gökden, Y , Oyman, F . "A new biological marker in inflammatory bowel disease: Pentraxin 3" . Journal of Surgery and Medicine 4 (2020 ): 875-878 <http://jsurgmed.com/en/pub/issue/57049/791156>
Chicago Kalyon, S , Gökden, Y , Oyman, F . "A new biological marker in inflammatory bowel disease: Pentraxin 3". Journal of Surgery and Medicine 4 (2020 ): 875-878
RIS TY - JOUR T1 - A new biological marker in inflammatory bowel disease: Pentraxin 3 AU - Semih Kalyon , Yasemin Gökden , Fırat Oyman Y1 - 2020 PY - 2020 N1 - doi: 10.28982/josam.791156 DO - 10.28982/josam.791156 T2 - Journal of Surgery and Medicine JF - Journal JO - JOR SP - 875 EP - 878 VL - 4 IS - 10 SN - -2602-2079 M3 - doi: 10.28982/josam.791156 UR - https://doi.org/10.28982/josam.791156 Y2 - 2020 ER -
EndNote %0 Journal of Surgery and Medicine A new biological marker in inflammatory bowel disease: Pentraxin 3 %A Semih Kalyon , Yasemin Gökden , Fırat Oyman %T A new biological marker in inflammatory bowel disease: Pentraxin 3 %D 2020 %J Journal of Surgery and Medicine %P -2602-2079 %V 4 %N 10 %R doi: 10.28982/josam.791156 %U 10.28982/josam.791156
ISNAD Kalyon, Semih , Gökden, Yasemin , Oyman, Fırat . "A new biological marker in inflammatory bowel disease: Pentraxin 3". Journal of Surgery and Medicine 4 / 10 (October 2020): 875-878 . https://doi.org/10.28982/josam.791156
AMA Kalyon S , Gökden Y , Oyman F . A new biological marker in inflammatory bowel disease: Pentraxin 3. J Surg Med. 2020; 4(10): 875-878.
Vancouver Kalyon S , Gökden Y , Oyman F . A new biological marker in inflammatory bowel disease: Pentraxin 3. Journal of Surgery and Medicine. 2020; 4(10): 875-878.
IEEE S. Kalyon , Y. Gökden and F. Oyman , "A new biological marker in inflammatory bowel disease: Pentraxin 3", Journal of Surgery and Medicine, vol. 4, no. 10, pp. 875-878, Oct. 2020, doi:10.28982/josam.791156